Development and in vitro evaluation of polyurethane microparticles as carrier for bevacizumab: an alternative treatment for retinopathy of prematurity

Authors

  • Ramona C Albulescu 2nd Pediatrics Dept. Faculty of Medicine Victor Babes University of Medicine and Pharmacy, Timisoara
  • Florin Borcan Pharm. Chemistry Dept. Faculty of Pharmacy Victor Babes University of Medicine and Pharmacy, Timisoara
  • Corina Paul 2nd Pediatrics Dept. Faculty of Medicine Victor Babes University of Medicine and Pharmacy, Timisoara
  • Iulian Velea 2nd Pediatrics Dept. Faculty of Medicine Victor Babes University of Medicine and Pharmacy, Timisoara
  • Maria Puiu 3Genetics Dept. Faculty of Medicine Victor Babes University of Medicine and Pharmacy, Timisoara

DOI:

https://doi.org/10.3329/icpj.v3i6.18759

Keywords:

, Bevacizumab, Polyurethane Carrier, Simulated Body Fluid, Phosphate Buffered Saline, Ultrasound

Abstract

Retinopathy of prematurity (ROP) is known as an abnormal development of the blood capillaries from the eyes retina, and it is met to those infants that were born too early (premature) as its name suggests. Bevacizumab or Avastin belongs to the class of monoclonal antibodies and it is a possible treatment for those patients who have been diagnosed with a recurrent malignant glioma or other cancers due to its behavior to bind selectively to vascular endothelial growth factor (VEGF). In this study, eye drops based on a polyurethane carrier used for bevacizumab were obtained and the degradation of this carrier was studied for three weeks in two different media: simulated body fluid (SBF) and phosphate buffered saline (PBS); the influence of ultrasounds on the degradation of polyurethane carrier was also evaluated. The obtained results suggest that the polyurethane carrier presents a very slow degradation which is beneficial for drugs which require low release rates and on the other hand, the concentrations of the degradation products remain at a low level.

DOI: http://dx.doi.org/10.3329/icpj.v3i6.18759

International Current Pharmaceutical Journal, May 2014, 3(6): 275-279

Downloads

Download data is not yet available.
Abstract
208
PDF
70

Downloads

Published

2014-05-03

How to Cite

Albulescu, R. C., Borcan, F., Paul, C., Velea, I., & Puiu, M. (2014). Development and in vitro evaluation of polyurethane microparticles as carrier for bevacizumab: an alternative treatment for retinopathy of prematurity. International Current Pharmaceutical Journal, 3(6), 275–279. https://doi.org/10.3329/icpj.v3i6.18759

Issue

Vol. 3 No. 6 (2014)

Section

Original Articles

License

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).